CORDIS
EU research results

CORDIS

English EN
Utility of omic-based biomarkers in characterizing older individuals at risk for frailty, its progression to disability and general consequences to health and well-being - The FRAILOMIC Initiative

Utility of omic-based biomarkers in characterizing older individuals at risk for frailty, its progression to disability and general consequences to health and well-being - The FRAILOMIC Initiative

Objective

The forecasted increase in the number of older people for this century will be accompanied by an increase of those with disabilities. Disability is usually preceded by a condition named frailty that encompasses changes associated with ageing, life styles and chronic diseases. To detect and intervene on it is of outstanding importance to prevent disability, as recovery from disability is unlikely. Recent documents stress the necessity of testing the clinical utility (in terms of risk prediction, diagnosis validity and prognostic significance) of the existing definition of frailty by using combinations of clinical criteria (current definition) and lab Biomarkers (BMs).
We will measure the levels of blood and urine omic-based BMs in old people selected from eight cohorts, which include up to 75,000 participants, using standardized and innovative technology (WP1). This figure will allow us to test the research questions with a high power and validity. Combining these lab BMs with clinical BMs, we will develop predictive, diagnostic and prognostic models (WP2), with its modulation by nutrition and physical activity, in general old population and in old people showing some characteristics that confer a high risk for developing frailty (selected cardiovascular risk factors and diseases) (WP4). After that, a selected set of BMs will be validated prospectively (WP3) and assessed to find the best-fitted models (WP4). These models will guide the development of the ready-to-use kits to be implemented in the clinical settings. These kits will be at the center of dissemination and exploitation activities (WP5, WP6).
A well-balanced consortium distributed over the individual tasks in the respective work packages will carry it out, with a strong participation of SMEs. In summary, FRAILOMIC is original, relevant, pertinent, feasible, overcome the usual research bottlenecks on Biomarkers, and fits perfectly with the topics addressed by the HEALTH.2012.2.1.1-2 call in human subjects

Coordinator

SERVICIO MADRILENO DE SALUD

Address

Plaza Carlos Trias Bertran 7
28020 Madrid

Spain

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 649 365,85

Administrative Contact

Luis Julian Fernandez Vera (Mr.)

Participants (27)

Sort alphabetically

Sort by EU Contribution

Expand all

AZIENDA SANITARIA DI FIRENZE

Italy

WORLD HEALTH ORGANIZATION

Switzerland

EU Contribution

€ 780 600

LIFE LENGTH SL

Spain

EU Contribution

€ 401 600

YH YOUHEALTH AB

Sweden

EU Contribution

€ 922 400

EVERCYTE GMBH

Austria

EU Contribution

€ 592 222

SISTEMAS GENOMICOS SL

Spain

EU Contribution

€ 824 666

MOSAIQUES DIAGNOSTICS GMBH

Germany

EU Contribution

€ 599 888,40

INNOVACION DESARROLLO Y TRANSFERE

Spain

EU Contribution

€ 260 600

NICHE SCIENCE & TECHNOLOGY LTD

United Kingdom

EU Contribution

€ 263 200

UNIVERSITY OF BEDFORDSHIRE

United Kingdom

EU Contribution

€ 31 140,09

UNIVERSIDAD AUTONOMA DE MADRID

Spain

EU Contribution

€ 586 090

CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE

France

EU Contribution

€ 177 200

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 419 142

ISTITUTO NAZIONALE DI RIPOSO E CURA PER ANZIANI INRCA

Italy

AZIENDA UNITA' SANITARIA LOCALE TOSCANA CENTRO

Italy

EU Contribution

€ 447 010

AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA

Italy

EU Contribution

€ 440 500

UNIVERSITAET INNSBRUCK

Austria

EU Contribution

€ 546 598,44

CARDIFF METROPOLITAN UNIVERSITY

United Kingdom

EU Contribution

€ 441 612,60

FRIEDRICH-SCHILLER-UNIVERSITAT JENA

Germany

EU Contribution

€ 303 105,28

UNIVERSITAT DE VALENCIA

Spain

EU Contribution

€ 596 520

SAN RAFFAELE S.p.A.

Italy

EU Contribution

€ 130 315

UNIVERSITE DE BORDEAUX

France

EU Contribution

€ 344 500

CONSIGLIO NAZIONALE DELLE RICERCHE

Italy

EU Contribution

€ 254 375

DIABETES FRAIL LIMITED

United Kingdom

EU Contribution

€ 411 259,91

DEUTSCHES INSTITUT FUER ERNAEHRUNGSFORSCHUNG POTSDAM REHBRUECKE

Germany

EU Contribution

€ 201 974,71

SERVICIO DE SALUD DE CASTILLA LA MANCHA

Spain

EU Contribution

€ 274 458,15

UNIVERSIDAD DE CASTILLA - LA MANCHA

Spain

EU Contribution

€ 40 000

Project information

Grant agreement ID: 305483

Status

Closed project

  • Start date

    1 January 2013

  • End date

    30 June 2018

Funded under:

FP7-HEALTH

  • Overall budget:

    € 15 491 422,98

  • EU contribution

    € 11 940 343,43

Coordinated by:

SERVICIO MADRILENO DE SALUD

Spain